Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Aug;56(8):1220-3.
doi: 10.1373/clinchem.2009.137596.

Opiate-positive immunoassay screen in a pediatric patient

Joely A Straseski  1 , Andrew Stolbach, William Clarke
Affiliations
Case Reports

Opiate-positive immunoassay screen in a pediatric patient

Joely A Straseski et al. Clin Chem. 2010 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: W. Clarke, Thermo Fisher Scientific.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: W. Clarke, Thermo Fisher Scientific and the HIV Prevention Trials Network (HPTN) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Office of AIDS Research, of the NIH, Department of Health and Human Services (U01-AI-068613).

Expert Testimony: None declared.

Figures

Fig. 1
Fig. 1. Cross-reactivity of naloxone with an opiate CEDIA
Rate reflects the change in absorbance units per minute subtracted from the rate obtained for the 300-μg/L cutoff calibrator. Dashed line indicates the threshold for positivity. Inset: naloxone concentrations between 6000 μg/L and 7000 μg/L.
See this image and copyright information in PMC

Comment in

  • Commentary.
    Porter WH. Porter WH. Clin Chem. 2010 Aug;56(8):1223-4. doi: 10.1373/clinchem.2010.149658. Clin Chem. 2010. PMID: 20668170 No abstract available.
  • Commentary.
    Lowry JA. Lowry JA. Clin Chem. 2010 Aug;56(8):1224-5. doi: 10.1373/clinchem.2010.149666. Clin Chem. 2010. PMID: 20668171 No abstract available.

References

    1. Porter WH. Clinical toxicology. In: Burtis CA, Ashwood ER, Bruns DE, editors. Teitz textbook of clinical chemistry and molecular diagnostics. 4. St. Louis: Elsevier Saunders; 2006. pp. 1287–369.
    1. Tornabene VW. Narcotic withdrawal syndrome caused by naltrexone. Ann Intern Med. 1974;81:785–7. - PubMed
    1. Osterhoudt KC, Ewald MB, Shannon M, Henretig FM. Toxicologic emergencies. In: Fleisher GR, Ludwig S, Henretig FM, editors. Textbook of pediatric emergency medicine. 5. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 953.
    1. Howland MA. Opioid antagonists. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, editors. Goldfrank’s toxicologic emergencies. 8. New York: McGraw-Hill; 2006. pp. 614–9.
    1. American Academy of Pediatrics Committee on Drugs. Naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children. Pediatrics. 1990;86:484–5. - PubMed

Publication types